How much does a box of Zilucoplan currently cost? Is it expensive?

Zilucoplan (Zilucoplan) is a new small molecule drug targeting the complement system. It is mainly used to treat adult patients with acetylcholine receptor antibody-positive (AChR-Ab+) myasthenia gravis (rare disease) . This drug is injected subcutaneously once a day and acts on the complement C5 protein to block terminal complement activation, thereby alleviating myasthenia symptoms. Due to its complex molecular structure and highly specific target, no generic drugs or biosimilars are currently available.

From a drug pricing perspective, Zeleptide has not yet been approved for marketing in mainland China, nor has it been included in the national medical insurance catalog, so it cannot be purchased through regular hospital channels in China. At present, if patients need medication, they mainly rely on cross-border drug purchase or overseas medical channels. According to public information, Zeleputide subcutaneous injection (16.6mg/0.416ml) is relatively expensive in overseas markets. The price of each box (usually containing about 28 tubes) is roughly between 22,000 and 28,000 US dollars. Based on the U.S. dollar exchange rate, the equivalent of RMB can reach hundreds of thousands or even higher.

The high cost makes it currently a small-scale trial drug in China, and is only available to those who have financial means and obtain it through formal overseas medical channels. Since the drug is still classified as a treatment for rare diseases, the manufacturer has formulated a high-cost pricing strategy for it. This pricing not only includes research and development expenses, but also involves factors such as cold chain transportation, clinical supervision, and patent protection. There is currently no clear signal for generic drugs to enter the market, and there is no expectation that other competing products will significantly reduce treatment costs. Therefore, price reductions may be limited in the short term.

In general, zeleptide is a high-priced product in the global drug market. Although it has certain clinical breakthrough significance in the treatment of myasthenia gravis, it has not yet been popularized among a wide range of patients due to high drug prices and regional access restrictions, especially in the Chinese market, which is still at a blank stage.

Reference materials:https://www.drugs.com/zilucoplan.html